Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylases (HDACs) regulate gene expression, cell proliferation, and differentiation, making them key cancer targets.
• Microtubules, crucial for cell structure and function, are also vital targets in anticancer drug research.
• Multi-target therapy offers a strategy to enhance antitumor efficacy and overcome drug resistance.

Purpose of the Study:

• To review recent advancements in dual-targeting inhibitors of HDACs and tubulin.
• To explore the impact of these dual inhibitors on anticancer drug discovery.
• To highlight the benefits of combining HDAC and tubulin inhibition.

Main Methods:

• Literature review of recent studies (last decade) on HDAC/tubulin dual inhibitors.
• Analysis of the synergistic effects and reduced toxicities of dual-targeting agents.
• Evaluation of the impact on anticancer drug discovery and development.

Main Results:

• Development of novel HDAC/tubulin dual inhibitors has progressed significantly.
• These dual inhibitors demonstrate synergistic anticancer activity.
• Combined inhibition leads to decreased toxicity and drug resistance compared to single-target agents.

Conclusions:

• HDAC/tubulin dual-targeting inhibitors represent a promising strategy in cancer therapy.
• This approach optimizes therapeutic efficacy and minimizes adverse effects.
• Further research into these dual inhibitors is crucial for advancing anticancer drug discovery.